Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Christopher Greer

Ophthalmology Fort Smith, AR Doctor of Osteopathy

NPI 1457379083 CMS profile 1173392

6801 Rogers Ave, Fort Smith, AR 72903

Open in the dashboard

General payments

$1,655

48 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Christopher Greer of Fort Smith, AR is reported in the CMS Open Payments database as having received $1,655 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $90 5
2022 General $209 12
2021 General $46 3
2020 General $61 4
2019 General $1,249 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Greer
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Christopher Greer were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Christopher Greer Ophthalmology median Middle half National median
2019 $1,249 $258 $104–$655 $163
2020 $61 $126 $45–$321 $114
2021 $46 $205 $76–$534 $132
2022 $209 $266 $100–$678 $149
2023 $90 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,033 4 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $290 25 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $110 6 payments
  4. Alcon Vision LLC $79 4 payments
  5. Braintree Laboratories, Inc. $27 2 payments
  6. Regeneron Healthcare Solutions, Inc. $19 1 payment
  7. TissueTech, Inc. $19 1 payment
  8. AbbVie, Inc. $19 1 payment
  9. Sun Pharmaceutical Industries Inc. $16 1 payment
  10. Eyevance Pharmaceuticals LLC $16 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 2 payments
  2. Food and Beverage $655 46 payments
Products named General payments · program years 2019–2023
  1. VYZULTA $1,030 4 payments
  2. PROLENSA $1,018 3 payments
  3. LOTEMAX $1,000 2 payments
  4. BESIVANCE $515 2 payments
  5. ALREX $500 1 payment
  6. TRULANCE Gastroenterology $118 14 payments
  7. ENTYVIO $96 5 payments
  8. TRULANCE Gastroenterology $94 5 payments
  9. XIFAXAN $93 7 payments
  10. APRISO $89 11 payments
  11. Other $356 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Ophthalmology: 891

Drug cost

$74

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 13 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record